For research use only. Not for therapeutic Use.
GLPG-1837 (Cat.No:I014394), also known as ABBV-974, is a novel cystic fibrosis transmembrane conductance regulator (CFTR) potentiator1. GLPG1837 was generally safe and well tolerated in healthy subjects up to the highest dose of 800 mg twice daily for 2 weeks. GLPG1837 shows enhanced efficacy on CFTR mutants harboring Class III mutations compared to Ivacaftor, the first marketed potentiator.
| Catalog Number | I014394 |
| CAS Number | 1654725-02-6 |
| Synonyms | GLPG-1837; GLPG 1837; GLPG1837; ABBV-974; ABBV 974; ABBV974.;N-(3-carbamoyl-5,5,7,7-tetramethyl-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-3-carboxamide |
| Molecular Formula | C16H20N4O3S |
| Purity | ≥95% |
| Target | Autophagy |
| Solubility | Soluble in DMSO |
| IUPAC Name | N-(3-carbamoyl-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide |
| InChI | InChI=1S/C16H20N4O3S/c1-15(2)7-8-10(12(17)21)14(24-11(8)16(3,4)23-15)19-13(22)9-5-6-18-20-9/h5-6H,7H2,1-4H3,(H2,17,21)(H,18,20)(H,19,22) |
| InChIKey | GHTGYZMBQPXTCQ-UHFFFAOYSA-N |
| SMILES | O=C(C1=NNC=C1)NC(S2)=C(C(N)=O)C3=C2C(C)(C)OC(C)(C)C3 |
